Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | PDE6C | P51160 | 2/20 | 0.79 |
| ▸ | PDE6D | O43924 | 1/20 | 0.79 |
| ▸ | PDE6A | P16499 | 1/20 | 0.79 |
| ▸ | PDE6G | P18545 | 1/20 | 0.79 |
| ▸ | PDE6B | P35913 | 1/20 | 0.79 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210977 | 0.90 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL23295122 | 0.89 | PDE5A (0.90) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL15131967 | 0.88 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL16211000 | 0.87 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL16211056 | 0.85 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL30753349 | 0.85 | PDE5A (0.82) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL15131970 | 0.85 | PDE5A (0.82) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL15131973 | 0.85 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL16220178 | 0.80 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G | |
| SCHEMBL16220024 | 0.79 | PDE5A (1.00) | PDE5APDE6CPDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-26 | — | — | US | disclosed |
| US-10626113-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| EP-3022205-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20140329804-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2014-11-06 | — | — | US | disclosed |
| US-20140329804-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 22/4885PDE6D 27/4885 |
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 20/4885PDE6D 26/4885 |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 20/4885PDE6D 26/4885 |
| US-10626113-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 20/4885PDE6D 26/4885 |
| US-20140329804-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 22/4885PDE6D 27/4885 |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 22/4885PDE6D 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.